Quartz·2 min read·medium
Novo Nordisk is asking a court to immediately block Eli Lilly's weight loss drug ads
✦AI Summary
Novo Nordisk is seeking a court injunction to stop Eli Lilly from running advertisements for its weight loss drugs, Zepbound and Mounjaro. Novo claims the advertisements use outdated data and fail to mention newer, more effective versions of their own competing products.
Novo says Lilly's ads for Zepbound and Mounjaro rely on outdated data and omit newer, higher-dose versions of Wegovy and Ozempic
businesshealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in